SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...
An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday. As the first Bruton's tyrosine kinase (BTK) inhibitor ...
Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet ...
Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or ...
Please provide your email address to receive an email when new articles are posted on . Patients with immune thrombocytopenia achieved durable platelet count expansion with rilzabrutinib.
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results